Effect of Azeliragon on Treatment-Resistant Metastatic Pancreatic Cancer

A Phase I/II Open Label Study to Assess Safety and Preliminary Evidence of a Therapeutic Effect of Azeliragon in Patients Refractory to Prior Treatment of Metastatic Pancreatic Cancer

This study is testing a new drug called azeliragon to see if it can help people with advanced pancreatic cancer who haven't had success with other treatments.

Quick facts

• Phase: PHASE1; PHASE2
• Study type: Interventional
• Enrollment: 30 (estimated)
• Ages: 18 Years to 80 Years
• Sex: All
• Sponsor: Cantex Pharmaceuticals (industry)
• Drugs / interventions: chemotherapy
• Locations: 6 sites (Los Angeles, California and 5 other locations)
• Trial ID: NCT05766748 on ClinicalTrials.gov

What this trial studies

This open-label study evaluates the safety and preliminary therapeutic effects of azeliragon in patients with metastatic pancreatic cancer who have not responded to prior treatments. Participants must have histologically confirmed locally advanced or metastatic adenocarcinoma of the pancreas and have previously undergone treatment with specific chemotherapy regimens. The study aims to gather data on the drug's efficacy and safety profile in this challenging patient population.

Who should consider this trial

Good fit: Ideal candidates are adults aged 18 to 80 with confirmed metastatic pancreatic cancer who have previously been treated with Gemcitabine/Abraxane or FOLFIRINOX.

Not a fit: Patients who have not undergone prior chemotherapy or those with resectable tumors may not benefit from this study.

Why it matters

Potential benefit: If successful, this treatment could provide a new option for patients with metastatic pancreatic cancer who have exhausted other therapies.

How similar studies have performed: While there have been studies on treatments for metastatic pancreatic cancer, the specific use of azeliragon in this context is novel and has not been extensively tested.

Eligibility criteria

Inclusion Criteria:

1. Patient must have histologically confirmed locally advanced or metastatic adenocarcinoma of the pancreas for which potential curative measures, such as resection of an isolated metastasis, are not available.
2. Patient should have previously been treated with a Gemcitabine/Abraxane or FOLFIRINOX- based regimen.
3. Toxicity from prior chemotherapy other than alopecia has recovered to Grade ≤ 1 (CTCAE 1.0) or are at baseline (such as stable G2 neuropathy).
4. Male or non-pregnant and non-lactating female and ≥ 18 to ≤ 80 years of age.
5. Patient has adequate biological parameters as demonstrated by the following blood counts at Screening (obtained ≤ 14 days prior to enrollment) and at Baseline-Day 0: Absolute neutrophil count (ANC) ≥ 1.0 × 109/L; Platelet count ≥ 75,000/mm3 (75 × 109/L); Hemoglobin (Hgb) ≥ 9 g/dL without transfusion or growth factor support
6. Patient has the following blood chemistry levels at Screening (obtained ≤ 14 days prior to enrollment) and at Baseline-Day 0:

   * AST (SGOT), ALT (SGPT) ≤ 2.5 × upper limit of normal range (ULN), unless liver metastases are present, then ≤ 5 x ULN is acceptable. Total bilirubin ≤ 1.5 × ULN.
   * Estimated creatinine clearance of \> 60 mL/min (per Cockroft-Gault formula)
7. Patient has ECOG performance status of ≤ 2
8. Patient has been informed about the nature of the study, and has agreed to participate in the study, and signed the Informed Consent Form prior to participation in any study-related activities.

Exclusion Criteria:

1. Patient has a life expectancy, per investigator assessment, of less than 3 months.
2. Patient has experienced an increase of ECOG to \> 2 between Screening and the time of first dose with study drug.
3. Patient has active, uncontrolled bacterial, or fungal infection(s) requiring systemic therapy.
4. Patients receiving CYP 2C8 inhibitors noted in Section 5.3 of the protocol.
5. Patient has a concomitant serious medical or psychiatric illness that, in the opinion of the investigator, could compromise the patient's safety or the study data integrity.
6. Patient is unwilling or unable to comply with study procedures, including, but not limited to self-administration of oral medication.
7. Patients with a gastrointestinal condition that could interfere with swallowing or absorption.
8. Females of childbearing potential who are sexually active or males with female partners of childbearing potential, where either the female or the male is unwilling to use a highly effective method of contraception during the trial and for 6 months after the last administration of study drug.
9. Patients with concurrent participation in another interventional clinical trial or use of another investigational agent within 14 days of starting study drug. Patients who are participating in non-interventional clinical trials (e.g., quality of life, imaging, observational, follow-up studies, etc.) are eligible, regardless of the timing of participation.

Where this trial is running

Los Angeles, California and 5 other locations

• Cedars-Sinai Medical Center, Samuel Oschin Comprehensive Cancer Institute — Los Angeles, California, United States (RECRUITING)
• Boca Raton Regional Hospital, Lynn Cancer Institute — Boca Raton, Florida, United States (RECRUITING)
• Williamette Valley Cancer Institute and Research Center — Eugene, Oregon, United States (RECRUITING)
• AHN Cancer Institute - Allegheny General Hospital — Pittsburgh, Pennsylvania, United States (RECRUITING)
• Prisma Health - Upstate — Greenville, South Carolina, United States (RECRUITING)
• Texas Oncology - Northeast Texas — Tyler, Texas, United States (RECRUITING)

Study contacts

• Principal investigator: Andrew Hendifar, MD — Cedars-Sinai Medical Center, Samuel Oschin Comprehensive Cancer Institute
• Study coordinator: Stephen Marcus, MD

Conditions: Metastatic Pancreatic Cancer, azeliragon